Does Multivit-Min-Mfolate 800 Mcg DFE-Vitamin K 150 Mcg-Herb No.289 Tablet Interact with other Medications?
Severe Interactions
These medications are not usually taken together. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation.
- STRONG CYP3A4 INHIBITORS/MAVORIXAFOR (> 200 MG)
- STRONG CYP3A4 INHIBITORS/GEPIRONE
- CYP1A2 INHIBITORS/FEZOLINETANT
- WEAK CYP3A4 INHIBITORS/LEMBOREXANT (> 5 MG)
- STRONG CYP3A4 INHIB; PROTEASE INHIB/LUMATEPERONE (>10.5 MG)
- SELECTED STRONG CYP3A4 INHIBITORS/ALPRAZOLAM; TRIAZOLAM
- STRONG CYP3A4 INHIBITORS; ATAZANAVIR;DARUNAVIR/LERCANIDIPINE
- WEAK CYP3A4 INHIBITORS/LOMITAPIDE (>30 MG)
- STRONG CYP3A4 INHIBITORS/PANOBINOSTAT (> 10 MG)
- SELECTED STRONG CYP3A4 INHIBITORS/ERGOT ALKALOIDS
- STRONG CYP3A4 INHIBITORS/SLT HIGH STRENGTH ANTIMUSCARINICS
- ANTICHOLINERGICS; ANTISPASMODICS/PRAMLINTIDE
- SELECTED CYP3A4 INHIBITORS/LOVASTATIN; SIMVASTATIN
- AMYLASE; PANCREATIN/ACARBOSE; MIGLITOL
- STRONG CYP3A4 INHIBITORS/VARDENAFIL (>2.5 MG)
Serious Interactions
These medications may interact and cause very harmful effects. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation.
- STRONG CYP3A4 INHIBITORS/AMIODARONE
- P-GLYCOPROTEIN (P-GP) INHIBITORS/VINCRISTINE
- STRONG AND MODERATE CYP3A4 INHIBITORS/NIROGACESTAT
- STRONG CYP3A4 INHIBITORS/CAPIVASERTIB
- STRONG AND MODERATE CYP3A4 INHIBITORS/REPOTRECTINIB
- CYP3A4 INDUCERS/ZURANOLONE
- P-GLYCOPROTEIN (P-GP) INHIBITORS/PRALSETINIB
- CYP3A4 INDUCERS/ERLOTINIB
- STRONG CYP3A4 INHIBITORS/PALOVAROTENE
- SELECTED STRONG CYP3A4 INHIBITORS/TACROLIMUS
- GINKGO BILOBA/UBROGEPANT
- P-GLYCOPROTEIN (P-GP) INHIBITORS/BILASTINE
- STRONG CYP3A4 INHIBITORS/UPADACITINIB (>=30 MG)
- SELECTED MODERATE AND WEAK CYP1A2 INHIBITORS/TIZANIDINE
- CYP3A4 INDUCERS/ATOGEPANT
- P-GLYCOPROTEIN (P-GP) INHIBITORS/DOXORUBICIN
- SELECTED CYP3A4 INHIBITORS/CARBAMAZEPINE
- P-GLYCOPROTEIN (P-GP) INHIBITORS/RELUGOLIX
- STRONG CYP3A4 INHIBITORS/PAZOPANIB
- STRONG CYP3A4 INHIBITORS/NILOTINIB
- DUAL STRONG CYP3A4 AND P-GP INHIBITORS/PRALSETINIB
- STRONG CYP3A4 INHIBITORS/LURBINECTEDIN
- STRONG AND MODERATE CYP3A4 INHIBITORS/PEMIGATINIB
- CYP3A4 INDUCERS/LUMATEPERONE
- P-GLYCOPROTEIN (P-GP) INHIBITORS/ORAL LEFAMULIN
- STRONG CYP3A4 INHIBITORS/ENTRECTINIB
- WEAK CYP3A4 INHIBITORS/ELIGLUSTAT
- STRONG CYP3A4 INHIB;MODERATE 3A4 & P-GP DUAL INHIB/NERATINIB
- SLT STRONG 3A4 INHIBITORS/SILDENAFIL(PAH);TADALAFIL(BPH,PAH)
- SELECTED P-GLYCOPROTEIN (P-GP) INHIBITORS/VENETOCLAX
- SELECTED INHIBITORS OF P-GP OR BCRP/PAZOPANIB
- WEAK CYP3A4 INHIBITORS/LOMITAPIDE (<=30MG)
- AGENTS THAT AFFECT IODIDE/RADIOACTIVE IODIDE
- P-GLYCOPROTEIN (P-GP) INHIBITORS/TOPOTECAN
- SELECTED P-GLYCOPROTEIN (P-GP) INHIBITORS/DABIGATRAN
- SELECTED CYP3A4 INHIBITORS/SELECTED OPIOIDS
- VITAMIN K/SELECTED ANTICOAGULANTS (VITAMIN K ANTAGONISTS)
Moderate Interactions
These medications may cause some risk when taken together. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation.
- P-GLYCOPROTEIN (P-GP) INHIBITORS/MAVORIXAFOR
- STRONG CYP3A4 INHIBITORS/MAVORIXAFOR
- POLYVALENT CATIONS AND PHOSPHATE BINDERS/VADADUSTAT
- STRONG AND MODERATE CYP3A4 INHIBITORS/ETRASIMOD
- STRONG CYP3A4 INHIB; PROTEASE INHIB/LUMATEPERONE (<=10.5 MG)
- MODERATE AND WEAK CYP3A4 INDUCERS/TACROLIMUS
- STRONG CYP3A4 INHIBITORS/UPADACITINIB (<30 MG)
- FOLIC ACID/PAFOLACIANINE
- SLT MODERATE AND WEAK CYP3A4 INHIBIT/SIROLIMUS PROTEIN-BOUND
- POLYVALENT CATIONS/ROXADUSTAT
- POLYVALENT CATIONS/CABOTEGRAVIR
- STRONG OR MODERATE CYP2D6 OR CYP3A4 INHIBITORS/OLICERIDINE
- MODERATE AND WEAK CYP3A4 INDUCERS/UBROGEPANT
- WEAK CYP3A4 INHIBITORS/UBROGEPANT
- WEAK CYP3A4 INHIBITORS/LEMBOREXANT (<= 5 MG)
- MODERATE AND WEAK CYP3A4 INHIBITORS/TACROLIMUS
- SELECTED MINERALS, ORAL/TRIENTINE
- FAT SOLUBLE VITAMINS/COLESEVELAM
- POLYVALENT CATIONS/BALOXAVIR
- SELECT P-GP INHIBITORS/EDOXABAN (<= 30 MG)
- POLYVALENT CATIONS; SUCRALFATE/BICTEGRAVIR
- SEL ORAL CATIONS; ANTACIDS; H2 ANTAG/DOLUTEGRAVIR-RILPIVIRIN
- SELECTED MODERATE CYP3A4 INHIBITORS/ACALABRUTINIB
- SELECTED P-GLYCOPROTEIN (P-GP) INHIBITORS/BETRIXABAN
- SELECTED CYP3A4 INHIBITORS/FELODIPINE
- SELECT P-GP INHIBITORS/EDOXABAN (> 30 MG)
- SELECTED CYP1A2 INHIBITORS/THEOPHYLLINE DERIVATIVES
- SELECTED MODERATE-WEAK CYP3A4 INDUCERS/EXEMESTANE
- STRONG 3A4 INHIB/LEVOMILNACIPRAN(<=80MG);VILAZODONE(<=20MG)
- SELECTED ORAL CATIONS/DOLUTEGRAVIR
- P-GLYCOPROTEIN (P-GP) INHIBITORS/AFATINIB
- SELECTED ORAL CATIONS/ELVITEGRAVIR
- SELECTED ORAL CATIONS/SELECTED ORAL QUINOLONES
- GLUCOSAMINE AND-OR CHONDROITIN/COUMARIN ANTICOAGULANTS
- STRONG CYP3A4 INHIBITORS/VARDENAFIL (<=2.5 MG)
- SELECTED ORAL CATIONS/SELECTED ORAL QUINOLONES
- STRONG CYP3A4 INHIBITORS/PANOBINOSTAT (<= 10 MG)
- SLT STRONG CYP3A4 INHIBIT/SELECTED CALCIUM CHANNEL BLOCKERS
- POLYVALENT CATIONS/ELTROMBOPAG
- GINKGO BILOBA/MIDAZOLAM
- GINKGO BILOBA/TOLBUTAMIDE
- DI-; TRIVALENT CATIONS/CHLOROQUINE; HYDROXYCHLOROQUINE
- ORAL MULTIVALENT CATIONS/ORAL BISPHOSPHONATES
- CYP3A4; CYP2C8; P-GLYCOPROTEIN (P-GP) INHIBITORS/LOPERAMIDE
- FAT SOLUBLE VITAMINS/ORLISTAT
- STRONG CYP3A4 INHIBITORS/SLT LOW STRENGTH ANTIMUSCARINICS
- SLT STRONG CYP3A4 INHIBITORS/SILDENAFIL (ED); TADALAFIL (ED)
- DIVALENT & TRIVALENT CATIONS/TETRACYCLINES
- FOLIC ACID; PYRIMETHAMINE/HYDANTOINS
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.